Trials / Unknown
UnknownNCT05583357
Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351
A Single Center, Randomized, Open-labeled, Blind Endpoint Evaluation, Exploratory Clinical Study to Evaluate the Safety and Immunogenicity of Bivalent Vaccine V-01D-351 as a Booster Dose in Participants Aged 18 Years and Older Vaccinated 2-dose or 3-dose Inactivated COVID-19 Vaccine
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Livzon Pharmaceutical Group Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
It is a single center, randomized, open-labeled, blind endpoint evaluation, exploratory clinical study to evaluate the safety and immunogenicity of bivalent vaccine V-01D-351 as a booster.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | V-01D-351 | One dose of V-01D-351 on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago |
| BIOLOGICAL | V-01D-351 | One dose of V-01D-351 on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago |
| BIOLOGICAL | CoronaVac | One dose of CoronaVac on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago |
| BIOLOGICAL | CoronaVac | One dose of CoronaVac on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago |
Timeline
- Start date
- 2022-08-15
- Primary completion
- 2022-09-13
- Completion
- 2023-08-10
- First posted
- 2022-10-17
- Last updated
- 2022-10-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05583357. Inclusion in this directory is not an endorsement.